- Dr Fakih on OS Data for Sotorasib Plus Panitumumab in KRAS G12C+ mCRCby OncLive articles on June 27, 2024
Marwan G. Fakih, MD, discusses data for sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.
- Dr O’Shaughnessy on MammaPrint H1 vs H2 Status on 3-year RFS in HR+, HER2– Breast Cancerby OncLive articles on June 27, 2024
Joyce O’Shaughnessy, MD, on the impact of MammaPrint H1 and H2 status on 3-year relapse-free survival in HR-positive, HER2-negative early breast cancer.
- Dr Maakaron on Choosing Between Bispecific Antibodies and CAR T-Cell Therapy in DLBCLby OncLive articles on June 27, 2024
Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.
- Dr O’Malley on Updates in Gynecologic Oncology at the 2024 ASCO Annual Meetingby OncLive articles on June 27, 2024
David M. O’Malley, MD, and Chandler H. Park, MD, FACP, discuss updates in gynecologic oncology at the 2024 ASCO Annual Meeting.
- Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple Myelomaby OncLive articles on June 27, 2024
Mohamad Mohty, MD, PhD, discusses the real-world efficacy of elranatamab in patients with relapsed/refractory multiple myeloma.
- Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual Meetingby OncLive articles on June 27, 2024
Suresh S. Ramalingam, MD, FACP, FASCO, and Chandler H. Park, MD, FACP, discuss updates in non–small cell lung cancer at the 2024 ASCO Annual Meeting.
- Dietrich and Shiller on the Importance of Oncology Reflex Testingby OncLive articles on June 27, 2024
- Lunresertib Plus FOLFIRI Shows Safety, Elicits Responses in CCNE1+ or FBXW7+ Advanced GI Tumorsby OncLive articles on June 27, 2024
Lunresertib plus FOLFIRI was safe and produced responses in advanced gastrointestinal tumors harboring CCNE1 amplifications or FBXW7 alterations.
- Dr Gross on the Neoadjuvant Utility of Cemiplimab in CSCCby OncLive articles on June 27, 2024
Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab in the treatment of patients with cutaneous squamous cell carcinoma.
- Adding Celecoxib to Adjuvant Chemotherapy Offers DFS, OS Benefit in PIK3CA-Mutated Stage III Colon Cancerby OncLive articles on June 27, 2024
Celecoxib plus adjuvant chemotherapy led to extended DFS and OS vs placebo plus adjuvant chemotherapy in PIK3CA-mutated stage III colon cancer.
- Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testingby OncLive articles on June 27, 2024
Drs Dietrich and Shiller detail the importance of collaboration between medical oncologists and pathologists to ensure beneficial oncology reflex testing.
- Breaking New Ground in Biological Therapies for Cancerby OncLive articles on June 27, 2024
The financial performance of Florida Cancer Specialists & Research Institute for the first two months of 2024 surpassed the statewide practice’s budget.
- Ficerafusp Alfa/Pembrolizumab Demonstrates Clinically Meaningful Activity in Metastatic HNSCCby OncLive articles on June 27, 2024
The bifunctional antibody ficerafusp alfa plus pembrolizumab generated clinically meaningful activity in HPV–recurrent/metastatic HNSCC.
- MPO Could Represent Predictive OS Biomarker for CM24 Plus Nivolumab/Chemo in Second-Line PDACby OncLive articles on June 27, 2024
MPO may be a predictive biomarker for survival for treatment with CM24, nivolumab, and chemotherapy in second-line pancreatic ductal adenocarcinoma.
- FDA Modifies REMS for Autologous CAR T-Cell Therapies in Hematologic Malignanciesby OncLive articles on June 27, 2024
The FDA has modified the risk evaluation and mitigation strategies for CAR T-cell therapies approved for hematologic malignancies.
- Lutetium Lu 177 Dotatate Enters the Pediatric Treatment Paradigm for SSTR+ GEP-NETsby OncLive articles on June 27, 2024
Daniel M. Halperin, MD, details the FDA approval of lutetium Lu 177 dotatate as well as safety and efficacy data in pediatric and adult patients treated with the agent.
- FDA Issues CRL for Patritumab Deruxtecan in Pretreated EGFR+ NSCLCby OncLive articles on June 27, 2024
The FDA has issued a complete response letter to the BLA for patritumab deruxtecan in pretreated advanced EGFR-mutated non–small cell lung cancer.
- Zanidatamab in Previously-Treated HER2-Positive (HER2+) Biliary Tract Cancer (BTC): Overall Survival (OS) and Longer Follow-up From the Phase 2b HERIZON-BTC-01 Studyby OncLive articles on June 27, 2024
Zanidatamab is a HER2-targeted bispecific antibody that binds to two non-overlapping HER2 domains and crosslinks neighboring HER2 proteins. In the primary analysis of the phase 2b HERIZON-BTC-01 trial (NCT04466891), after a median follow-up of 12.4 […]
- Intracranial Efficacy of Datopotamab Deruxtecan in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From TROPION-Lung05by OncLive articles on June 27, 2024
Tropion-Lung05 (NCT04484142) is a phase 2, multicenter, single-arm, open-label study evaluating Dato-DXd in patients with advanced/metastatic NSCLC with actionable genomic alterations who have progressed on or after targeted therapy and […]
- Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Yearsby OncLive articles on June 27, 2024
Liso-cel continued to show improved disease control and EFS and PFS vs SOC in the second-line treatment of patients with large B-cell lymphoma.
- Dr Cigliola on the Efficacy of Sacituzumab Govitecan in MIBCby OncLive articles on June 27, 2024
Antonio Cigliola, MD, discusses interim efficacy data from the SURE-01 study investigating neoadjuvant sacituzumab govitecan in patients with MIBC.
- Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCLby OncLive articles on June 27, 2024
Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.